Author:
Matsukura Suchitra,Nakamura Yuji,Hoshiai Kiyotaka,Hayashi Takashi,Koga Tadashi,Goto Ai,Chiba Koki,Lubna Nur Jaharat,Hagiwara-Nagasawa Mihoko,Izumi-Nakaseko Hiroko,Ando Kentaro,Naito Atsuhiko T.,Sugiyama Atsushi
Subject
Pharmacology,Molecular Medicine
Reference18 articles.
1. ICH Harmonised Tripartite Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-Antiarrhythmic drugs E14. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf. Accessed 29 March 2018.
2. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes;Van;Drug Saf,2009
3. Effects of three fluoroquinolones on QT analysis after standard treatment courses;Tsikouris;Ann Noninvasive Electrocardiol,2006
4. Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase;Darpo;Clin Pharmacol Ther,2015
5. E14 Implementation Working Group ICH E14 Guideline. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions & Answers (R3). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Q_As_R3__Step4.pdf. Accessed 29 March 2018.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献